Latest Insider Transactions at Voyager Therapeutics, Inc. (VYGR)
This section provides a real-time view of insider transactions for Voyager Therapeutics, Inc. (VYGR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Voyager Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Voyager Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 02
2024
|
Sandell Jacquelyn Fahey Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
5,999
-6.52%
|
$29,995
$5.82 P/Share
|
|
Oct 01
2024
|
Nathan D. Jorgensen Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
80,000
+50.0%
|
-
|
|
Apr 02
2024
|
Alfred Sandrock President and CEO |
SELL
Open market or private sale
|
Direct |
12,115
-3.62%
|
$109,035
$9.86 P/Share
|
|
Apr 02
2024
|
Robin Swartz Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,357
-1.15%
|
$12,213
$9.88 P/Share
|
|
Apr 01
2024
|
Toby Ferguson Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
105,000
+50.0%
|
-
|
|
Feb 21
2024
|
Alfred Sandrock President and CEO |
SELL
Open market or private sale
|
Direct |
13,033
-3.75%
|
$91,231
$7.46 P/Share
|
|
Feb 21
2024
|
Robin Swartz Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
3,966
-3.24%
|
$27,762
$7.45 P/Share
|
|
Feb 21
2024
|
Todd Alfred Carter Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,365
-3.7%
|
$23,555
$7.47 P/Share
|
|
Feb 21
2024
|
Peter P. Pfreundschuh Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,764
-2.1%
|
$26,348
$7.46 P/Share
|
|
Feb 20
2024
|
Todd Alfred Carter Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
602
-0.66%
|
$4,214
$7.68 P/Share
|
|
Feb 09
2024
|
Sandell Jacquelyn Fahey Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
31,000
+25.2%
|
-
|
|
Feb 09
2024
|
Alfred Sandrock President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
130,000
+27.2%
|
-
|
|
Feb 09
2024
|
Robin Swartz Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+29.01%
|
-
|
|
Feb 09
2024
|
Todd Alfred Carter Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
38,500
+29.59%
|
-
|
|
Feb 09
2024
|
Peter P. Pfreundschuh Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+14.32%
|
-
|
|
Jan 17
2024
|
Todd Alfred Carter Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,266
-2.33%
|
$8,862
$7.18 P/Share
|
|
Jan 17
2024
|
Robin Swartz Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,543
-3.4%
|
$17,801
$7.15 P/Share
|
|
Oct 03
2023
|
Peter P. Pfreundschuh Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
13,567
-8.32%
|
$81,402
$6.99 P/Share
|
|
Oct 01
2023
|
Sandell Jacquelyn Fahey Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
61,000
+50.0%
|
-
|
|
Sep 15
2023
|
Todd Alfred Carter Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
10,500
-16.19%
|
$84,000
$8.16 P/Share
|
|
Sep 15
2023
|
Todd Alfred Carter Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+7.16%
|
$10,000
$2.85 P/Share
|
|
Jul 06
2023
|
Todd Alfred Carter Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,500
-8.41%
|
$55,000
$10.8 P/Share
|
|
Jun 30
2023
|
Todd Alfred Carter Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,000
-7.11%
|
$55,000
$11.41 P/Share
|
|
Jun 30
2023
|
Todd Alfred Carter Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+6.63%
|
$10,000
$2.85 P/Share
|
|
Apr 03
2023
|
Alfred Sandrock President and CEO |
SELL
Open market or private sale
|
Direct |
7,437
-3.35%
|
$52,059
$7.83 P/Share
|
|
Apr 03
2023
|
Robin Swartz Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,259
-1.73%
|
$8,813
$7.83 P/Share
|
|
Mar 20
2023
|
Robert W. Hesslein Senior VP & General Counsel |
SELL
Open market or private sale
|
Direct |
4,410
-4.14%
|
$30,870
$7.76 P/Share
|
|
Mar 20
2023
|
Robin Swartz Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
3,654
-4.77%
|
$25,578
$7.76 P/Share
|
|
Mar 20
2023
|
Todd Alfred Carter Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,193
-3.25%
|
$15,351
$7.76 P/Share
|
|
Mar 15
2023
|
Robin Swartz Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
15,373
-16.73%
|
$122,984
$8.2 P/Share
|
|
Feb 23
2023
|
Neurocrine Biosciences Inc > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
4,395,588
+33.89%
|
$35,164,704
$8.88 P/Share
|
|
Feb 17
2023
|
Peter P. Pfreundschuh Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
38,000
+18.91%
|
-
|
|
Feb 17
2023
|
Todd Alfred Carter Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
738
-1.08%
|
$5,166
$7.45 P/Share
|
|
Feb 17
2023
|
Todd Alfred Carter Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
34,000
+33.24%
|
-
|
|
Feb 17
2023
|
Robert W. Hesslein Senior VP & General Counsel |
SELL
Open market or private sale
|
Direct |
3,297
-3.0%
|
$23,079
$7.45 P/Share
|
|
Feb 17
2023
|
Alfred Sandrock President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
120,000
+35.08%
|
-
|
|
Feb 17
2023
|
Robin Swartz Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+30.33%
|
-
|
|
Feb 13
2023
|
Robert W. Hesslein Senior VP & General Counsel |
SELL
Open market or private sale
|
Direct |
2,868
-2.54%
|
$20,076
$7.67 P/Share
|
|
Feb 13
2023
|
Todd Alfred Carter Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
797
-2.27%
|
$5,579
$7.67 P/Share
|
|
Feb 02
2023
|
Third Rock Ventures Iii, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
1,500,000
-32.02%
|
-
|
|
Feb 01
2023
|
Third Rock Ventures Iii, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
128,642
-2.67%
|
$1,157,778
$9.32 P/Share
|
|
Jan 31
2023
|
Third Rock Ventures Iii, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
185,000
-3.7%
|
$1,665,000
$9.25 P/Share
|
|
Jan 30
2023
|
Third Rock Ventures Iii, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
75,000
-1.48%
|
$675,000
$9.03 P/Share
|
|
Jan 27
2023
|
Third Rock Ventures Iii, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
50,000
-0.98%
|
$450,000
$9.02 P/Share
|
|
Jan 25
2023
|
Third Rock Ventures Iii, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
50,000
-0.97%
|
$450,000
$9.22 P/Share
|
|
Jan 24
2023
|
Third Rock Ventures Iii, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
100,000
-1.9%
|
$900,000
$9.27 P/Share
|
|
Jan 23
2023
|
Third Rock Ventures Iii, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
55,000
-1.03%
|
$495,000
$9.06 P/Share
|
|
Jan 20
2023
|
Third Rock Ventures Iii, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
100,000
-1.84%
|
$900,000
$9.15 P/Share
|
|
Jan 17
2023
|
Todd Alfred Carter Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,106
-1.54%
|
$9,954
$9.96 P/Share
|
|
Jan 17
2023
|
Robert W. Hesslein Senior VP & General Counsel |
SELL
Open market or private sale
|
Direct |
2,188
-0.96%
|
$19,692
$9.96 P/Share
|